HEALTH
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects – Reuters
- Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects Reuters
- Novo Nordisk’s amylin obesity drug keeps performing like Zepbound STAT
- Novo hunts for ‘maximum potential’ from obesity drug CagriSema Financial Times
- Novo Nordisk’s CagriSema Shot Tied to Greater Weight Loss at Lower Doses Bloomberg.com
- CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM Yahoo Finance
Source link
